Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Rosiglitazone and fenofibrate additive effects on lipids.

Slim A, Castillo-Rojas L, Hulten E, Slim JN, Pearce Moore D, Villines TC.

Cholesterol. 2011;2011:286875. doi: 10.1155/2011/286875. Epub 2011 Nov 24.

3.

Effects of fenofibrate on albuminuria in patients with hypertriglyceridemia and/or hyperuricemia: a multicenter, randomized, double-blind, placebo-controlled, crossover study.

Kazumi T, Hirano T, Yoshino G, For The Fenofibrate Study Group.

Curr Ther Res Clin Exp. 2003 Jul;64(7):434-46. doi: 10.1016/S0011-393X(03)00127-9.

5.

Effects of fenofibrate on lipids, lipoproteins, and apolipoproteins in 33 subjects with primary hypercholesterolemia.

Mellies MJ, Stein EA, Khoury P, Lamkin G, Glueck CJ.

Atherosclerosis. 1987 Jan;63(1):57-64.

PMID:
3548734
7.

Fenofibrate reduces systemic inflammation markers independent of its effects on lipid and glucose metabolism in patients with the metabolic syndrome.

Belfort R, Berria R, Cornell J, Cusi K.

J Clin Endocrinol Metab. 2010 Feb;95(2):829-36. doi: 10.1210/jc.2009-1487. Epub 2010 Jan 8.

9.

Free fatty acid metabolism during fenofibrate treatment of the metabolic syndrome.

Vega GL, Cater NB, Hadizadeh DR 3rd, Meguro S, Grundy SM.

Clin Pharmacol Ther. 2003 Sep;74(3):236-44.

PMID:
12966367
10.

Differential effect of fenofibrate and atorvastatin on in vivo kinetics of apolipoproteins B-100 and B-48 in subjects with type 2 diabetes mellitus with marked hypertriglyceridemia.

Hogue JC, Lamarche B, Deshaies Y, Tremblay AJ, Bergeron J, Gagné C, Couture P.

Metabolism. 2008 Feb;57(2):246-54. doi: 10.1016/j.metabol.2007.09.008.

PMID:
18191056
11.

Effect of fenofibrate treatment on plasma lipoprotein lipids, high-density lipoprotein cholesterol subfractions, and apolipoproteins B, AI, AII, and E.

Knopp RH, Walden CE, Warnick GR, Albers JJ, Ginsberg J, McGinnis BM.

Am J Med. 1987 Nov 27;83(5B):75-84.

PMID:
3120587
13.
14.

The effect of dual PPAR alpha/gamma stimulation with combination of rosiglitazone and fenofibrate on metabolic parameters in type 2 diabetic patients.

Seber S, Ucak S, Basat O, Altuntas Y.

Diabetes Res Clin Pract. 2006 Jan;71(1):52-8. Epub 2005 Jul 11.

PMID:
16009445
16.
18.

Fenofibrate affects the compositions of lipoproteins.

Goldberg AC, Schonfeld G, Anderson C, Dillingham MA.

Am J Med. 1987 Nov 27;83(5B):60-5.

PMID:
3318455
19.

Synergistic improvement in insulin resistance with a combination of fenofibrate and rosiglitazone in obese type 2 diabetic mice.

Choi WS, Lee JJ, Kim Y, Kim IS, Zhang WY, Myung CS.

Arch Pharm Res. 2011 Apr;34(4):615-24. doi: 10.1007/s12272-011-0412-9. Epub 2011 May 5.

PMID:
21544727

Supplemental Content

Support Center